Terapia Integrativa e Neurocognitiva Curta para Jovens Adultos com Transtorno de Personalidade Borderline (SINTYA)
Terapia Integrativa e Neurocognitiva Curta para Jovens Adultos com Transtorno de Personalidade Borderline: um Modelo de Estudo de Gerenciamento da Impulsividade
Borderline personality disorder (BPD) is a severe, high-suicidal psychiatric disorder associated with impulsive, endangering behaviors. Young patients between 16 and 25 years old do not respond to traditional psychotherapies, which are often long and not adapted to their neurocognitive alterations linked to early trauma. The study authors hypothesize the SINTYA therapy program (one group session and one individual session weekly for 10 weeks) would reduce the level of impulsivity and clinical symptomatology (severity of the BPD; emotional regulation difficulties; dissociative symptoms; aggressiveness; ruminations; the number of self-destructive behaviors and suicidal acts; impulsive behaviors; level of suicide risk and hopelessness; the number of psychiatric hospitalizations and emergency visits for psychiatric reasons; and finally improving psychosocial functioning).
Visão geral do estudo
Status
Status
Condições
Condições
Intervenção / Tratamento
Intervenção / Tratamento
Tipo de estudo
Tipo de estudo
Inscrição (Real)
Inscrição
Estágio
Estágio
- Não aplicável
Contactos e Locais
Locais de estudo
-
-
-
Nîmes, França
- CHU de Nîmes
-
-
Critérios de participação
Critérios de elegibilidade
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Diagnosis of BPD according to DSM-5 criteria and BPQ-80 scale.
- High BPD severity level: ZAN-BPD (score ≥ 18/36).
- Understand, write and read French.
- Be able to understand the nature, purpose and methodology of the study and agree to cooperate during evaluations.
- Have signed the informed consent.
- For minor patients, have signed the parental consent by at least one holder of parental authority.
Exclusion Criteria:
- Refusal to participate.
- Existence of a neurological pathology or cerebral sequelae of organic origin which could affect neurocognitive performance.
- Intelligence quotient < 70.
- Lifetime diagnosis of schizoaffective disorder or schizophrenia (MINI-7).
- Previous or current participation in specific psychotherapy for BPD.
- Subject deprived of liberty (by judicial or administrative decision) and/or protected by law.
- Inclusion in another study including psychotherapy for the duration of the study.
- Inclusion in a drug RIPH1 study or in a REC study (European regulation of clinical trials) for the entire duration of the study.
- Subject in period of exclusion from another research protocol.
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Randomizado
- Modelo Intervencional: Atribuição Paralela
- Mascaramento: Solteiro
Número de braços
Armas e Intervenções
Grupo de Participantes / BraçoGrupo de Participantes / Braço |
Intervenção / TratamentoIntervenção / Tratamento |
|---|---|
|
Sem intervenção: Ao controle
|
|
|
Experimental: Grupo SINTYA
|
10-week psychotherapy program consisting of a weekly 1h30 hour group therapy session plus 1 hour individual therapy session |
O que o estudo está medindo?
Medidas de resultados primários
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Variation in explicit impulsivity between groups
Prazo: Baseline
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Baseline
|
|
Variation in explicit impulsivity between groups
Prazo: Month 4
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Month 4
|
Medidas de resultados secundários
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Variation in explicit impulsivity between groups
Prazo: Month 7
|
UPPS-S (Impulsive Behavior Scale Short version score) |
Month 7
|
|
Variation in impulsiveness between groups
Prazo: Baseline
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Baseline
|
|
Variation in impulsiveness between groups
Prazo: Month 4
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Month 4
|
|
Variation in impulsiveness between groups
Prazo: Month 7
|
Barratt Impulsiveness Scale (BIS-11) (score out of 120) |
Month 7
|
|
BPD severity level between groups
Prazo: Baseline
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Baseline
|
|
BPD severity level between groups
Prazo: Month 4
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Month 4
|
|
BPD severity level between groups
Prazo: Month 7
|
Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD) (score out of 36) |
Month 7
|
|
Emotional regulation capacities between groups
Prazo: Baseline
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Baseline
|
|
Emotional regulation capacities between groups
Prazo: Month 4
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Month 4
|
|
Emotional regulation capacities between groups
Prazo: Month 7
|
Difficulties in Emotion Regulation Scale (DERS-18) |
Month 7
|
|
Dissociative symptoms between groups
Prazo: Baseline
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Baseline
|
|
Dissociative symptoms between groups
Prazo: Month 4
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Month 4
|
|
Dissociative symptoms between groups
Prazo: Month 7
|
Dissociative Experiences Scale (DES): a score of 25 or higher is predictive of dissociative disorder |
Month 7
|
|
Aggression between groups
Prazo: Baseline
|
Aggression Questionnaire (AQ-12) |
Baseline
|
|
Aggression between groups
Prazo: Month 4
|
Aggression Questionnaire (AQ-12) |
Month 4
|
|
Aggression between groups
Prazo: Month 7
|
Aggression Questionnaire (AQ-12) |
Month 7
|
|
Ruminations between groups
Prazo: Baseline
|
Rumination Reflection Questionnaire (RRQ) |
Baseline
|
|
Ruminations between groups
Prazo: Month 4
|
Rumination Reflection Questionnaire (RRQ) |
Month 4
|
|
Ruminations between groups
Prazo: Month 7
|
Rumination Reflection Questionnaire (RRQ) |
Month 7
|
|
Number of self-destructive behaviors between groups
Prazo: Baseline
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Baseline
|
|
Number of self-destructive behaviors between groups
Prazo: Month 4
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Month 4
|
|
Number of self-destructive behaviors between groups
Prazo: Month 7
|
Number of self-destructive/self-mutilatory/parasuicidal acts reported by the patient in a clinical interview |
Month 7
|
|
Number of impulsive behaviors between groups
Prazo: Baseline
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Baseline
|
|
Number of impulsive behaviors between groups
Prazo: Month 4
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Month 4
|
|
Number of impulsive behaviors between groups
Prazo: Month 7
|
Number of impulsive behaviors (food, motor vehicles, sexual, drug-related) |
Month 7
|
|
Level of suicide risk between groups
Prazo: Baseline
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Baseline
|
|
Level of suicide risk between groups
Prazo: Month 4
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Month 4
|
|
Level of suicide risk between groups
Prazo: Month 7
|
Columbia-Suicide Severity Rating Scale (C-SSRS) |
Month 7
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Prazo: 12 Months prior to inclusion
|
Information taken from patient medical file |
12 Months prior to inclusion
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Prazo: Baseline
|
Information taken from patient medical file |
Baseline
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Prazo: Month 4
|
Information taken from patient medical file |
Month 4
|
|
Number of psychiatric hospitalizations and emergency visits for psychiatric reasons between groups
Prazo: Month 7
|
Information taken from patient medical file |
Month 7
|
|
Psychosocial functioning between groups
Prazo: Baseline
|
Functional Assessment Staging Tool (FAST) |
Baseline
|
|
Psychosocial functioning between groups
Prazo: Month 4
|
Functional Assessment Staging Tool (FAST) |
Month 4
|
|
Psychosocial functioning between groups
Prazo: Month 7
|
Functional Assessment Staging Tool (FAST) |
Month 7
|
|
Implicit impulsivity between groups
Prazo: Baseline
|
Continuous Performance Test (CPT) |
Baseline
|
|
Implicit impulsivity between groups
Prazo: Month 4
|
Continuous Performance Test (CPT) |
Month 4
|
|
Implicit impulsivity between groups
Prazo: Month 7
|
Continuous Performance Test (CPT) |
Month 7
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Prazo: Baseline
|
Emotional Stroop (SE) customized to the study |
Baseline
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Prazo: Month 4
|
Emotional Stroop (SE) customized to the study |
Month 4
|
|
Neurocognitive evaluation of implicit impulsivity between groups
Prazo: Month 7
|
Emotional Stroop (SE) customized to the study |
Month 7
|
|
Risk taking between groups
Prazo: Baseline
|
Balloon Analogue Risk Task (BART) |
Baseline
|
|
Risk taking between groups
Prazo: Month 4
|
Balloon Analogue Risk Task (BART) |
Month 4
|
|
Risk taking between groups
Prazo: Month 7
|
Balloon Analogue Risk Task (BART) |
Month 7
|
|
Decision making under risk conditions between groups
Prazo: Baseline
|
Game Dice Task (GDT) |
Baseline
|
|
Decision making under risk conditions between groups
Prazo: Month 4
|
Game Dice Task (GDT) |
Month 4
|
|
Decision making under risk conditions between groups
Prazo: Month 7
|
Game Dice Task (GDT) |
Month 7
|
Colaboradores e Investigadores
Patrocinador
Patrocinador
Investigadores
Investigadores
- Investigador principal: Clémentine Estric, CHU de Nimes
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Início do estudo
Conclusão Primária (Real)
Conclusão Primária
Conclusão do estudo (Real)
Conclusão do estudo
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Primeira postagem
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última Atualização Postada
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Última verificação
Mais Informações
Termos relacionados a este estudo
Termos MeSH relevantes adicionais
Outros números de identificação do estudo
Outros números de identificação do estudo
- NIMAO/2022-1/CE-01
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
All IPD that underlie results in a publication
Prazo de Compartilhamento de IPD
Upon publication
Critérios de acesso de compartilhamento IPD
The IPD will be made available to other researchers upon reasonable request to the corresponding author
Tipo de informação de suporte de compartilhamento de IPD
- PROTOCOLO DE ESTUDO
- SEIVA
- CIF
- ANALYTIC_CODE
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .